Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis

4Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm.

Cite

CITATION STYLE

APA

Brennan, P. N., Dillon, J. F., & McCrimmon, R. (2022, September 22). Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. TouchREVIEWS in Endocrinology. https://doi.org/10.17925/EE.2022.18.2.148

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free